USCOM LIMITED — Regulatory Filings 2009

Jan 13, 2009

==> picture [80 x 96] intentionally omitted <==

MARKET ANNOUNCEMENT

Echoscope - New US patent for Uscom

Wednesday, 14th January 2009: Uscom (ASX Code: UCM) today received notice to grant its US patent no 10/523051 from the US Patents Office. The Patent describes a new USCOM based device for hand held use, much like a stethoscope. The notice to grant the US patent is recognition of the novelty and inventiveness of the method by the US Patent Office and provides commercial protection for development of the Echoscope by Uscom Ltd.

The Echoscope was conceived to provide for the acquisition of critical Doppler CO measurements using the Uscom method from a small hand held device which can be carried to remote non-hospital environments such as accident scenes or patient homes. Miniaturisation of devices is an important trend in medicine and the Echoscope will lead to increased portability and utility, and more widespread application of the Uscom technology. The device would have application in treatment of trauma, sepsis, heart failure and hypertension.

The patent author and Chairman of Uscom Ltd, Rob Phillips said “The Echoscope is a futuristic and potentially revolutionary application of the Uscom technology which will allow assessment of circulation rapidly at remote sites and will improve delivery of advanced levels of patient care. This patent confirms Uscom’s position as innovators and leaders in the field of cardiovascular measurement and monitoring.”

Uscom CEO, Paul Butler, said “I am pleased that we have secured the patent for this exciting technology. We can now plan the development of this product knowing that we have commercial protection in the market place for our intellectual property (IP). This patent allows for Uscom to strengthen its position in the cardiovascular device marketplace and is valuable for the Company.”

Uscom continues to develop IP as part of the process of developing innovative solutions to important clinical problems and it owns over 30 patents and intellectual protection applications in various stages of recognition around the world. This IP forms the commercial protection for a pipeline of new devices planned for development by the Company, and significantly contributes to shareholder value.

www.uscom.com.au

Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090

About Uscom

Uscom Limited (UCM) is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a non-invasive device for the safe and accurate measurement of cardiac output, as an alternative to the current invasive methods. The device provides real-time beat-to-beat information across multiple parameters of cardiac function and provides advanced trending capabilities, allowing clinicians to accurately quantify the effect of treatment. The device is ideally suited to Paediatrics, Intensive Care and Emergency Medicine, and Anaesthesia where it is critical to monitor changes in cardiac output as fluids and drugs are administered.

Uscom holds a number of national and international patents and patent applications predominantly related to cardiovascular assessment.

The Company has secured regulatory approval for sale of the USCOM 1A Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China. The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).

Uscom Contacts

Paul Butler Chief Executive Officer Office: 02 9247 4144 paul.butler@uscom.com.au

Rob Phillips Executive Chairman Office: 02 9247 4144 rob@uscom.com.au

www.uscom.com.au

Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090